10-Q: Biotricity Inc. Q1 2027 Earnings: Revenue Up, Net Loss Widens

Biotricity Inc. reported a 10.4% year-over-year revenue increase to $4.3 million for Q1 2027, driven by technology fees, though net loss widened to $0.96 million.

Summary

• Biotricity Inc. reported revenue of $4.3 million for the three months ended June 30, 2026, a 10.4% increase from $3.9 million in the same period last year.
• Gross profit margin improved to 82.6% from 80.5% year-over-year.
• Selling, general, and administrative expenses increased by 26.2% to $2.7 million, primarily due to higher share-based compensation.
• Net loss for the quarter was $0.96 million, compared to $0.67 million in the prior year quarter.
• The company has a working capital deficiency of $31.7 million as of June 30, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious outlook due to continued net losses and a working capital deficiency, despite revenue growth and improved gross margins.

Positives

• Revenue increased by 10.4% to $4.3 million for the three months ended June 30, 2026, compared to $3.9 million in the prior year.
• Recurring technology fee revenue grew by 23.6%, indicating strong customer retention and service quality.
• Gross profit margin improved to 82.6% from 80.5% year-over-year.
• The company has reported positive EBITDA of $90,409 for the quarter, although it decreased from $333,337 in the prior year.
• Positive Free Cash Flows were reported at $1.27 million for the three months ended June 30, 2026, up from $0.48 million in the prior year.

Negatives

• Net loss widened to $0.96 million for the three months ended June 30, 2026, from $0.67 million in the prior year quarter.
• Selling, general, and administrative expenses increased by 26.2% to $2.7 million, largely due to a significant rise in share-based compensation.
• The company has a working capital deficiency of $31.7 million as of June 30, 2026.
• The company has substantial doubt about its ability to continue as a going concern.
• The company's shares were delisted from The Nasdaq Capital Market due to non-compliance with minimum market value requirements.

Risks

• The company has incurred recurring losses from operations and has an accumulated deficit of $143.6 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may not be able to raise additional capital on acceptable terms, or at all, which could compromise its ability to execute its business plan.
• If additional funding is not obtained, the company may be required to modify its operating plan and curtail or slow the pace of development and commercialization.
• The company's ability to grow recurring revenue is predicated on the size and quality of its sales force and their ability to penetrate the market.

Future Outlook

Management anticipates continued revenue growth and improved liquidity through business development and additional capitalizations. However, the company will need to seek additional debt or equity capital to fund ongoing operations, protect intellectual property, develop new business lines, and enhance infrastructure. Failure to obtain funding could require modification of the operating plan and curtailment of development and commercialization efforts. The company believes its existing cash and anticipated near-term financings will be sufficient for the next twelve months, but acknowledges the need for further capital.

Management Comments

• Management believes the underlying trend - recurring revenue growth and margin expansion - supports its plan to achieve sustained operating profitability and positive cash flow, even as near-term results were affected by higher non-cash compensation expense.
• We believe our technological and clinical advantage combined with our solutions insourcing model, which empowers physicians with state-of-the-art technology and charges technology service fees for its use, has the benefit of a reduced operating overhead for us, and enables a more efficient market penetration and distribution strategy.
• Our mission is to innovate and create transformative healthcare products while ensuring financial discipline, to drive margin and revenue growth to deliver value creation for our investors.
• As growing patient numbers further stress the shortage of healthcare professionals, our technology could help alleviate this pressing issue.
• Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report.

Industry Context

StockSavvy.ai notes that Biotricity operates in the growing remote patient monitoring and telemedicine sector, which has seen increased adoption due to the COVID-19 pandemic. The company's focus on cardiac diagnostics and chronic care management aligns with industry trends towards preventative care and data-driven healthcare solutions. The increasing demand for AI in healthcare, projected to reach $208.2 billion by 2030, presents a significant opportunity for Biotricity's AI-enabled technologies.

Comparison to Industry Standards

• The company's gross margin of 82.6% is strong, particularly for a technology-focused healthcare company.
• The increase in SG&A expenses, driven by share-based compensation, is a common challenge for growth-stage technology companies, but the magnitude of the increase warrants attention.
• The company's net loss and working capital deficiency are typical for companies in the development and early commercialization phases of the medical technology industry, which often require significant upfront investment.
• The company's reliance on debt financing and the need for future capital raises are standard for companies in this sector seeking to scale operations and R&D.

Legal Proceedings

• The company is not currently a party to, and its property is not the subject of, any material legal proceedings.

Related Party Transactions

• Trade and other payables as of June 30, 2026, included $1,105,573 due to a shareholder who is a director and executive of the Company.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises; delisting from Nasdaq impacts liquidity and investor perception.
• Creditors: The company's working capital deficiency and going concern doubt may impact its ability to meet debt obligations.
• Employees: Increased share-based compensation expense may impact future profitability.
• Customers: Continued focus on customer retention and service quality is key to revenue growth.

Next Steps

• Continue to develop and commercialize Bioflux, Biocore, and Biocare products.
• Expand sales force and geographic footprint.
• Seek additional debt or equity capital to fund operations and growth.
• Continue to develop ancillary technologies requiring FDA clearances.
• Leverage AI technology for predictive monitoring tools and disease profiling.

Key Dates

Recommendation

While revenue growth and improving gross margins are positive, the widening net loss, substantial doubt about going concern, and significant working capital deficiency present considerable risks. The company's ability to secure future financing is critical. A 'hold' recommendation reflects a balance between the potential for future growth in a promising market and the significant financial challenges and uncertainties.

Keywords

remote patient monitoring, cardiac telemetry, medical technology, FDA clearance, revenue growth, net loss, share-based compensation, working capital deficiency